Stem Cell Umbilical Cord Blood Global Market Report 2025

The stem cell umbilical cord blood market size has grown rapidly in recent years. It will grow from $6.77 billion in 2024 to $7.98 billion in 2025 at a compound annual growth rate (CAGR) of 17.8%. This growth during the historical period can be credited to rising investments in research and development, heightened demand for private cord blood banking, a surge in clinical trial activities, a growing number of cancer cases, and an increase in fertility clinics worldwide.

The stem cell umbilical cord blood market size is expected to see rapid growth in the next few years. It will grow to $15.21 billion in 2029 at a compound annual growth rate (CAGR) of 17.5%. Factors contributing to this anticipated growth include the escalating incidence of chronic diseases, higher birth rates, growing interest in stem cell-based therapies, supportive governmental policies, and increasing emphasis on regenerative medicine. Noteworthy trends projected for this period include progress in therapeutic applications, improvements in healthcare infrastructure, innovations in cryopreservation technology, and the fusion of stem cell treatments with gene therapy advancements.

The rising childbirth rates are anticipated to drive the growth of the stem cell umbilical cord blood market in the coming years. Childbirth rates refer to the number of live births per 1,000 individuals in a population over a specific period, typically one year. The growth in childbirth rates is primarily attributed to the increased availability and affordability of fertility treatments, allowing more families to conceive. Umbilical cord blood stem cells are particularly valuable for newborns because they contain hematopoietic stem cells, which are instrumental in treating a range of blood, immune, and genetic disorders. These cells are genetically matched to the infant and may also be beneficial for siblings or other family members. For example, in April 2025, the U.S. Centers for Disease Control and Prevention reported that the number of births in the United States rose from 3,596,017 in 2023 to 3,622,673 in 2024, marking a 1% increase. As a result, the growing childbirth rates are significantly contributing to the expansion of the stem cell umbilical cord blood market.

Leading companies in the stem cell umbilical cord blood market are concentrating on developing innovative therapies and securing approvals, such as cord blood cell therapy for treating rare genetic disorders, enhancing immune system recovery, and supporting regenerative medicine initiatives. Cord blood cell therapy involves using stem cells obtained from umbilical cord blood to treat various medical conditions by regenerating or repairing damaged blood, immune, and tissue systems. For instance, in October 2024, StemCyte, a biotechnology company based in the United States, received regenerative medicine advanced therapy designation from the U.S. Food and Drug Administration (FDA) for its hematopoietic progenitor cell cord blood therapy (HPC Cord Blood) designed to treat Long COVID-19 syndrome. This cord blood cell therapy leverages umbilical cord stem cells to aid in healing and reduce inflammation. It has demonstrated promise in treating immune-related and degenerative disorders and offers a non-invasive, ethically sourced alternative for advanced regenerative therapies.

In July 2023, Leukaemia & Myeloma Research UK, a stem cell therapies organization based in the United Kingdom, partnered with Smart Cells International to offer funded storage of cord blood stem cells. This collaboration is intended to give families a secure and efficient method for collecting and preserving umbilical cord blood stem cells for future medical applications and research purposes. Smart Cells International, also headquartered in the UK, specializes in the collection and storage of umbilical cord blood stem cells.

Major players in the stem cell umbilical cord blood market are Takeda Pharmaceutical Company Limited, Global Cord Blood Corporation, Vita 34 AG, Cordlife Group Limited, StemLife Berhad, MediPost Co. Ltd., Smart Cells International Ltd., StemCyte Inc., Celularity Inc., Next Biosciences Pty Ltd, Esperite N.V., Cryo-Cell International Inc., FamiCord Group, Cells4Life Group LLP, Cryoviva Biotech Pvt. Ltd., Americord Registry LLC, ViaCord LLC, China Cord Blood Corporation, CBR Systems Inc., Cord Blood Registry.

North America was the largest region in the stem cell umbilical cord blood market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in stem umbilical cord blood report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the stem umbilical cord blood market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Umbilical cord blood stem cells are a unique type of cells obtained from the blood left in the umbilical cord and placenta following childbirth. This blood is a rich source of hematopoietic stem cells (HSCs), which can transform into various blood cells, including red blood cells, white blood cells, and platelets. These stem cells are widely used in medical treatments such as bone marrow transplants for individuals suffering from blood-related conditions like leukemia, lymphoma, and specific genetic disorders.

The key components of umbilical cord blood stem cells include both cord blood stem cells and cord tissue stem cells. Cord blood stem cells, which are hematopoietic in nature, are collected from a newborn’s umbilical cord and are utilized in treating blood and immune-related disorders. The technologies involved encompass cryopreservation, stem cell expansion, and cell separation. Storage options are divided among public cord blood banks, private cord blood banks, and hybrid models. The primary uses of stem cell umbilical cord blood span across hematologic diseases, metabolic disorders, immune deficiencies, neurological conditions, and more, catering to end-users such as hospitals, research centers, biotech firms, and others.

The stem cell umbilical cord blood market research report is one of a series of new reports that provides stem cell umbilical cord blood market statistics, including stem cell umbilical cord blood industry global market size, regional shares, competitors with a stem cell umbilical cord blood market share, detailed stem cell umbilical cord blood market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell umbilical cord blood industry. This stem cell umbilical cord blood market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem umbilical cord blood market consists of revenues earned by entities by providing services such as collection services, processing, testing, cryopreservation, storage, and transportation of cord blood, as well as related genetic screening and stem cell banking services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stem umbilical cord blood market also includes sales of whole cord blood units, isolated stem cell products, and cord blood expansion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.